Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma:: the role of preparative regimens

被引:63
作者
Salar, A
Sierra, J
Gandarillas, M
Caballero, MD
Manín, J
Lahuerta, JJ
García-Conde, J
Arranz, R
León, A
Zuazu, J
García-Laraña, J
López-Guillermo, A
Sanz, MA
Grañena, A
García, JC
Conde, E
机构
[1] Hosp Santa Creu & Sant Pau, Clin Hematol Div, Barcelona 08025, Spain
[2] Hosp Marques Valdecilla, Santander, Spain
[3] Hosp Clin Salamanca, Salamanca, Spain
[4] Hosp Nuestra Senora Aranzazu, San Sebastian, Spain
[5] Hosp 12 Octubre, E-28041 Madrid, Spain
[6] Hosp Clin Valencia, Valencia, Spain
[7] Hosp Princesa, Madrid, Spain
[8] Hosp Gen Jerez, Cadiz, Spain
[9] Hosp Gen Valle Hebron, Barcelona, Spain
[10] Hosp Ramon y Cajal, E-28034 Madrid, Spain
[11] Hosp Clin Barcelona, Barcelona, Spain
[12] Hosp La Fe, E-46009 Valencia, Spain
[13] Inst Catala Oncol, Barcelona, Spain
[14] Hosp Cruces, Vizcaya, Spain
关键词
high-dose therapy; preparative regimens; non-Hodgkin's lymphoma; prognostic factors; diffuse large cell lymphoma;
D O I
10.1038/sj.bmt.1702795
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We investigated the impact of the most commonly used preparative regimens on the outcome of 395 patients with diffuse large cell lymphoma (DLCL), consecutively reported to the registry of the Spanish GEL/TAMO, Among them, 139 (35%) were autografted in Ist CR, 86 (22%) in 2nd/3rd CR, 124 (31%) had chemosensitive disease and 46 (12%) had chemoresistant disease, Conditioning consisted of chemotherapy-only in 348 patients (BEAM, 164; BEAC, 145; and CBV, 39) and radiochemotherapy with CY and TBI in 47, Median times to granulocyte, platelet recovery and to discharge were significantly shorter in the chemotherapy-only group. Early transplant-related mortality was significantly higher when using CY-TBI, After a median follow-up of 28 months, overall survival (OS) at 8 years of patients conditioned with BEAM or BEAC (58% (95% CI 50-66%)) was more favorable than with CBV (40% (95% CI 24-56%)), and significantly better than with CY-TBI (31% (95 % CI 18-44%)). Multivariate analysis revealed that patients conditioned with chemotherapy-only regimens had improved OS, disease-free (DFS) and relapse-free survival (RFS) when compared to those conditioned with CY-TBI, Status at transplant was also a powerful prognostic indicator. We conclude that preparative regimens consisting of chemotherapy-only seem more efficacious than CY-TBI as conditioning for DLCL, because of faster engraftment and greater anti-lymphoma effect, as indicated by improved OS, DFS and RFS.
引用
收藏
页码:405 / 412
页数:8
相关论文
共 55 条
[1]   TREATMENT OF MALIGNANT-LYMPHOMA IN 100 PATIENTS WITH CHEMOTHERAPY, TOTAL-BODY IRRADIATION, AND MARROW TRANSPLANTATION [J].
APPELBAUM, FR ;
SULLIVAN, KM ;
BUCKNER, CD ;
CLIFT, RA ;
DEEG, HJ ;
FEFER, A ;
HILL, R ;
MORTIMER, J ;
NEIMAN, PE ;
SANDERS, JE ;
SINGER, J ;
STEWART, P ;
STORB, R ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) :1340-1347
[2]  
APPELBAUM FR, 1978, BLOOD, V52, P85
[3]   Malignant neoplasms following bone marrow transplantation [J].
Bhatia, S ;
Ramsay, NKC ;
Steinbuch, M ;
Dusenbery, KE ;
Shapiro, RS ;
Weisdorf, DJ ;
Robison, LL ;
Miller, JS ;
Neglia, JP .
BLOOD, 1996, 87 (09) :3633-3639
[4]  
Blay JY, 1998, BLOOD, V92, P3562
[5]  
Chan WC, 1997, BLOOD, V89, P3909
[6]  
CONDE E, 1994, BONE MARROW TRANSPL, V14, P279
[7]   RANDOMIZED COMPARISON OF MACOP-B WITH CHOP IN PATIENTS WITH INTERMEDIATE-GRADE NON-HODGKINS-LYMPHOMA [J].
COOPER, IA ;
WOLF, MM ;
ROBERTSON, TI ;
FOX, RM ;
MATTHEWS, JP ;
STONE, JM ;
DING, JC ;
DART, G ;
MATTHEWS, J ;
FIRKIN, FC ;
LOWENTHAL, RM ;
IRONSIDE, P .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :769-778
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]  
CRILLEY P, 1993, SEMIN ONCOL, V20, P50
[10]   INCIDENCE AND CHARACTERIZATION OF SECONDARY MYELODYSPLASTIC SYNDROME AND ACUTE MYELOGENOUS LEUKEMIA FOLLOWING HIGH-DOSE CHEMORADIOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR LYMPHOID MALIGNANCIES [J].
DARRINGTON, DL ;
VOSE, JM ;
ANDERSON, JR ;
BIERMAN, PJ ;
BISHOP, MR ;
CHAN, WC ;
MORRIS, ME ;
REED, EC ;
SANGER, WG ;
TARANTOLO, SR ;
WEISENBURGER, DD ;
KESSINGER, A ;
ARMITAGE, JO .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) :2527-2534